@article {Ellen ter2020.09.24.285940, author = {B.M. Ellen ter and N. Dinesh Kumar and E.M. Bouma and B. Troost and D.P.I. Pol van de and H.H. Ende van der-Metselaar and L. Apperloo and D. Gosliga van and M. Berge van den and M.C. Nawijn and P.H.J. Voort van der and J. Moser and I.A. Rodenhuis-Zybert and J.M. Smit}, title = {Resveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro}, elocation-id = {2020.09.24.285940}, year = {2020}, doi = {10.1101/2020.09.24.285940}, publisher = {Cold Spring Harbor Laboratory}, abstract = {The current COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has an enormous impact on human health and economy1. In search for therapeutic options, researchers have proposed resveratrol, a food supplement with known antiviral, anti-inflammatory and anti-oxidant properties as an advantageous antiviral therapy for SARS-CoV-2 infection2{\textendash}4. Here, we provide evidence that both resveratrol and its metabolically more stable structural analog, pterostilbene, exhibits potent antiviral properties against SARS-CoV-2 in vitro. Resveratrol and pterostilbene showed antiviral activity in African green monkey kidney cells and in human primary bronchial epithelial cells cultured in an air-liquid interface system. Mechanistic analyses demonstrated that both compounds actively interfere with the post-entry steps of virus replication cycle and their antiviral activity is long-lasting. Collectively, our data indicate that resveratrol and pterostilbene are promising antiviral compounds to treat SARS-CoV-2 infection and advocate evaluation of these compounds in clinical trialsCompeting Interest StatementThe authors have declared no competing interest.}, URL = {https://www.biorxiv.org/content/early/2020/09/24/2020.09.24.285940}, eprint = {https://www.biorxiv.org/content/early/2020/09/24/2020.09.24.285940.full.pdf}, journal = {bioRxiv} }